
The study highlights that transgender women are still at risk of developing prostate cancer and should be considered for prostate-specific antigen (PSA) screening. However, the current PSA reference ranges, and guidelines are based on data from cisgender men, which may not be appropriate for transgender women who are receiving gender-affirming hormones. The study recommends that transgender women undergo regular screening for prostate cancer and further evaluation if their PSA levels are above 1 ng/ml or if there is a rising trend. It is emphasized that patient-centered discussions should be initiated to ensure awareness of the risk of prostate cancer in transgender women. With more individuals openly identifying as transgender, it is crucial to improve our understanding and provide better care for transgender patients. Specifically, the article emphasizes the need for special consideration in cancer screening of the organs associated with their assigned birth sex.
Like
Save
Share